CT n=50 | TT n=84 | ICI n=159 | Overall n=293 | |
SARS-CoV-2-positive patients | 13 (26.0) | 24 (28.6) | 52 (32.7) | 89 (30.4) |
No occurrence of SAE | 11 (84.6) | 24 (100.0) | 43 (82.7) | |
Occurrence of SAE | 2 (15.4) | – | 9 (17.3) | |
SARS-CoV-2-negative patients | 37 (74.0) | 60 (71.4) | 107 (67.3) | 204 (69.6) |
No occurrence of SAE | 36 (97.3) | 60 (100.0) | 103 (96.3) | |
Occurrence of SAE | 1 (2.7) | – | 4 (3.7) | |
CMH test* | 0.0008* | |||
Breslow-Day test* | 0.8909 |
*Breslow-Day test: tests the homogeneity of the OR between the two groups.
†CMH: Cochran-Mantel-Haenszel test: tests the conditional independence between SAE and SARS-CoV-2 test result controlling for the type of therapy.
.CT, chemotherapy; ICI, immune checkpoint inhibitors; SAE, serious adverse event; TT, targeted therapy.